Form 4: Beam Therapeutics CEO Exercises, Sells Shares, Receives New Options

Beam Therapeutics CEO John M. Evans exercised stock options and sold a portion of the resulting shares, while also receiving a new grant of 180,000 stock options.

Summary

• John M. Evans, CEO and Director of Beam Therapeutics Inc., engaged in multiple equity transactions on January 29 and January 30, 2026.
• These transactions included the exercise of 50,000 stock options at an exercise price of $0.67 per share.
• Concurrently, Mr. Evans sold a total of 50,000 shares of common stock at weighted average prices ranging from $28.2734 to $29.7428 per share.
• All exercises and sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on May 16, 2025.
• Following these transactions, Mr. Evans directly owns 986,667 shares of common stock and indirectly owns 103,000 shares through the John M. Evans, III 2018 Irrevocable Trust.
• Additionally, on January 31, 2026, Mr. Evans was granted 180,000 new stock options with an exercise price of $27.62, which will vest monthly over 48 months.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction under a pre-arranged plan, balancing option exercises and sales with a new significant option grant, suggesting a neutral to slightly positive sentiment due to continued executive incentive.

Positives

• The CEO received a new grant of 180,000 stock options on January 31, 2026, indicating continued long-term incentive and alignment with company performance.
• Previous stock options, granted on May 8, 2018, vested due to the achievement of a closing price hurdle following BEAM's initial public offering and a specific development milestone related to base editing applications.

Negatives

• The CEO sold 50,000 shares of common stock, which, while part of a pre-arranged plan, represents a reduction in direct equity holdings.

Future Outlook

The newly granted 180,000 stock options will vest in equal monthly installments over the subsequent 48 months, subject to the CEO's continued service with Beam Therapeutics Inc. through each vesting date.

Management Comments

• Transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

Industry Context

StockSavvy.ai notes that Form 4 filings provide transparency into insider trading activities, which are closely monitored by investors for insights into management's perspective on the company's valuation and future prospects. While these transactions are company-specific, the use of a Rule 10b5-1 plan is a standard practice across industries for executives to manage their equity holdings in a compliant manner.

Corporate Governance

Related Party Transactions

• Indirect beneficial ownership of 103,000 shares through the John M. Evans, III 2018 Irrevocable Trust is reported.

Stakeholder Impact

• Shareholders may note the CEO's sale of shares, but the execution under a Rule 10b5-1 plan suggests a pre-planned liquidity event rather than a reaction to new information.
• The new option grant aligns the CEO's long-term incentives with shareholder value creation.

Next Steps

• Continued vesting of the 180,000 stock options granted on January 31, 2026, in equal monthly installments over the next 48 months, contingent on the CEO's continued service.

Key Dates

Recommendation

The filing details routine insider transactions by the CEO, including option exercises, subsequent share sales under a Rule 10b5-1 plan, and a new option grant. These actions are typical for executive compensation and liquidity management and do not inherently signal a change in the company's fundamental outlook or warrant a strong directional recommendation based solely on this report.

Keywords

Beam Therapeutics, BEAM, John M. Evans, Form 4, insider trading, stock options, share sale, 10b5-1 plan, CEO, director, equity